Both ACE inhibitors (0.81; 95% CrI 0.65–0.96; moderate confidence) and ARBs (0.76; 95% CrI 0.61–0.98; moderate confidence) were associated with a reduced risk of angina compared with placebo. The gene discussed is ACE; the disease is angina pectoris.